Search CORE

11 research outputs found

HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

Author: Andrea Antinori
Gianluigi Biava
Michele Bibas
Publication venue: PAGEPress Publications
Publication date: 01/07/2011
Field of study

HIV infection has been recognized as a prothrombotic condition and this association has now been proven by a large number of studies with a reported VTE frequency among HIV-infected patients ranging from 0.19% to 7,63 %/year. HIV infection is associated with a two to tenfold increased risk of venous thrombosis in comparison with a general population of the same age. Some risk factors demonstrated a strongest association with VTE such as, low CD4+ cell count especially in the presence of clinical AIDS, protein S deficiency, and protein C deficiency. Whereas other risk factors are still controversial like protease inhibitor therapy, presence of active opportunistic infections and presence of antiphospholipid antibodies, including anticardiolipin antibodies and lupus anticoagulant. Physicians caring for HIV positive patients should be able to recognize and treat not only the well-known opportunistic infections and malignancies associated with this chronic disease, but also be alert to the less well-known complications such as thromboses. Pulmonary embolism should be included in the differential diagnosis when patients with HIV/AIDS have unexplained dyspnea or hypoxemia. In younger individuals with VTE, especially men, without other identifiable risk factors for VTE, HIV should be considered. Because interactions between warfarin and antiretrovirals is possible, health care providers should also be alert to the potential of dangerously high or low INRs when they are giving anticoagulants to patients with HIV infection who are undergoing antiretroviral therapy.</p&gt

Directory of Open Access Journals

PubMed Central

HIV-ASSOCIATED VENOUS THROMBOEMBOLISM

Author: Andrea Antinori
Gianluigi Biava
Michele Bibas
Publication venue: 'Institute of Hematology, Catholic University'
Publication date
Field of study

Crossref

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.

Author: Emanuele Nicastri
Gianluigi Biava
Giuseppe Ippolito
INMI Ebola Team
Nicola Petrosillo
Pierangelo Chinello
Silvia Pittalis
Publication venue: 'Public Library of Science (PLoS)'
Publication date: 01/12/2017
Field of study

Directory of Open Access Journals

ECG registered on May 15, 2015.

Author: Emanuele Nicastri (310235)
Gianluigi Biava (4723515)
Giuseppe Ippolito (7056)
Nicola Petrosillo (341073)
Pierangelo Chinello (4723512)
Silvia Pittalis (4691452)
Publication venue
Publication date
Field of study

ECG registered on May 15, 2015.</p

FigShare

ECG registered on May 22, 2015.

Author: Emanuele Nicastri (310235)
Gianluigi Biava (4723515)
Giuseppe Ippolito (7056)
Nicola Petrosillo (341073)
Pierangelo Chinello (4723512)
Silvia Pittalis (4691452)
Publication venue
Publication date
Field of study

ECG registered on May 22, 2015.</p

FigShare

Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment

Author: Alessandro De Logu
Carlotta Marianecci
Federica Rinaldi
Gianluigi Cabiddu
Giovanna Poce
Jacopo Forte
Maria Carafa
Mariangela Biava
Patrizia Nadia Hanieh
Sara Consalvi
Publication venue: 'MDPI AG'
Publication date: 01/01/2022
Field of study

Tuberculosis remains one of the world’s deadliest infectious diseases, accounting for nearly 1.3 million deaths every year. Tuberculosis treatment is challenging because of the toxicity, decreased bioavailability at the target site of the conventional drugs and, most importantly, low adherence of patients; this leads to drug resistance. Here, we describe the development of suitable nanocarriers with specific physicochemical properties to efficiently deliver two potent antimyco- bacterial compounds. We prepared nanoemulsions and niosomes formulations and loaded them with two different MmpL3 inhibitors previously identified (NEs + BM635 and NIs + BM859). NEs + BM635 and NIs + BM859 were deeply characterized for their physicochemical properties and anti- mycobacterial activity. NEs + BM635 and NIs + BM859 showed good hydrodynamic diameter, ζ- Potential, PDI, drug-entrapment efficiency, polarity, and microviscosity and stability. Even though both formulations proved to perform well, only NIs + BM859 showed potent antimycobacterial ac- tivity against M. tuberculosis (MIC = 0.6 μM) compared to that of the free compound. This is most probably caused by the fact that BM635, being highly hydrophobic, encounters maximum hin- drance in diffusion, whereas BM859, characterized by high solubility in aqueous medium (152 μM), diffuses more easily. The niosomal formulation described in this work may be a useful therapeutic tool for tuberculosis treatment, and further studies will follow to characterize the in vivo behavior of the formulation

PubMed Central

Archivio della ricerca- Università di Roma La Sapienza

HIV infection as a permanent, acquired risk factor for VTE

Author: Andrea Antinori
C Dentan
G Guaraldi
Gianluigi Biava
I Martinelli
J Neuhaus
J Walston
JA Aberg
JV Baker
JV Baker
LD Rasmussen
LH Kuller
M Bibas
Michele Bibas
NT Funderburg
SG Deeks
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Crossref

Acute rhabdomyolysis and delayed pericardial effusion in an Italian patient with Ebola virus disease: a case report

Author: AK McElroy
Antonio Brucato
B Kreuels
D Sissoko
DP Bogdanos
Emanuele Nicastri
Gianluigi Biava
Giuseppe Ippolito
GR Cellarier
J Agua-Agum
M Mora-Rillo
MA Bwaka
Nicola Petrosillo
Timothy M. Uyeki
TM Uyeki
Publication venue: 'Springer Science and Business Media LLC'
Publication date
Field of study

Crossref

QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient

Author: CQ Bai
D Sissoko
DA Alves
DS Chertow
EJ Hoorn
Emanuele Nicastri
F Mentré
Gianluigi Biava
Giuseppe Ippolito
KA Rodvold
L Oestereich
M Traebert
M Van Herp
Manuel Schibler
Nicola Petrosillo
P Chinello
Pierangelo Chinello
RB Martines
RC Owens
Silvia Pittalis
SM Al-Khatib
V Sueblinvong
Y Furuta
Y Furuta
Y Kumagai
Publication venue: 'Public Library of Science (PLoS)'
Publication date
Field of study

Crossref